Amicus Therapeutics Inc. diskutieren
Amicus Therapeutics Inc.
WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Aktie / Pharmazeutika / Mid Cap /
8,75 €
-2,78 %
Sell Amicus Therapeutics Inc.
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at UBS Group AG from $15.00 to $17.00. They now have a "buy" rating on the stock.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $19.00. They now have an "overweight" rating on the stock.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $15.00.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $22.00 price target on the stock.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Bank of America Co. from $14.00 to $13.00. They now have a "buy" rating on the stock.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Morgan Stanley from $20.00 to $19.00. They now have an "overweight" rating on the stock.
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at UBS Group AG from $20.00 to $19.00. They now have a "buy" rating on the stock.
Ratings data for FOLD provided by MarketBeat
Neueste Beiträge
dryfirewood in Discuss V.F. Corp.